# Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

> **NCT03774446** · PHASE2 · RECRUITING · sponsor: **Cedars-Sinai Medical Center** · enrollment: 13 (estimated)

## Conditions studied

- Cushing Disease

## Interventions

- **DRUG:** Seliciclib

## Key facts

- **NCT ID:** NCT03774446
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-02
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03774446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03774446, "Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03774446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*